Freier S, Weiss O, Eran M, Flyvbjerg A, Dahan R, Nephesh I, Safra T, Shiloni E, Raz I
Laboratory of Mucosal Immunology, Shaare Zedek Medical Center, Jerusalem, Israel.
Gut. 1999 May;44(5):704-8. doi: 10.1136/gut.44.5.704.
To study changes in the expression of insulin-like growth factors (IGFs) and their receptors, as well as production of the IGF-I and IGF-II polypeptides, in adenocarcinoma of the colon.
Malignant tissue obtained at operation was used. Total RNA was extracted and specific IGF-I and IGF-II and their receptor mRNAs were measured by a solution hybridisation RNase protection assay. IGF-I and IGF-II polypeptides were measured by specific immunoassays.
All normal tissues expressed IGF-II, IGF-I receptor, and IGF-II/mannose-6-phosphate (Man-6-P) receptor. IGF-I mRNA could not be detected but the polypeptide was present in small but equal amounts in normal and malignant tissue. IGF-II was expressed 40 times more abundantly in colonic tumours than in adjacent normal tissue and the concentration of the corresponding polypeptide was twice as high in the malignant tissue. IGF-I receptor expression was increased by a factor of 2.5 and IGF-II/Man-6-P receptor by a factor of 4.
This study confirms that in adenocarcinoma of the human colon there is increased expression of IGF-I receptor and IGF-II. Furthermore, IGF-II/Man-6-P receptor message is increased and the increase in IGF-II message is accompanied by a doubling of the IGF-II protein in the tumour tissue compared with the adjacent normal tissue. These findings suggest that the IGF-II/Man-6-P receptor may also be involved in development of adenocarcinoma of the colon. There is rapidly accumulating evidence implicating the IGF system in the development of malignancy of the large bowel.
研究胰岛素样生长因子(IGFs)及其受体的表达变化,以及结肠腺癌中IGF-I和IGF-II多肽的产生情况。
使用手术获取的恶性组织。提取总RNA,通过溶液杂交核糖核酸酶保护试验测量特定的IGF-I、IGF-II及其受体mRNA。通过特异性免疫测定法测量IGF-I和IGF-II多肽。
所有正常组织均表达IGF-II、IGF-I受体和IGF-II/甘露糖-6-磷酸(Man-6-P)受体。未检测到IGF-I mRNA,但该多肽在正常组织和恶性组织中含量少但相等。IGF-II在结肠肿瘤中的表达量比相邻正常组织高40倍,恶性组织中相应多肽的浓度是正常组织的两倍。IGF-I受体表达增加了2.5倍,IGF-II/Man-6-P受体表达增加了4倍。
本研究证实,在人类结肠腺癌中,IGF-I受体和IGF-II的表达增加。此外,IGF-II/Man-6-P受体信息增加,与相邻正常组织相比,肿瘤组织中IGF-II信息的增加伴随着IGF-II蛋白含量加倍。这些发现表明,IGF-II/Man-6-P受体也可能参与结肠腺癌的发生发展。越来越多的证据表明IGF系统与大肠恶性肿瘤的发生有关。